Life Biosciences
CompanyUnited States
Life Biosciences develops one asset, in phase 1 (ER-100 in glaucoma). Mostly gene therapy acting on SOX2, epigenetic regulation of gene expression and KLF4; based in the United States.
- Assets
- 1
- Furthest
- Phase 1
- Trials
- 1
- Signals
- 0
Pipeline
1AAV-delivered, inducible OSK gene therapy for epigenetic reprogramming and cellular rejuvenation.
Phase 1Gene therapySOX2Epigenetic regulation of gene expressionglaucomaNAION
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms4
- Trials1
- People8
- Signals1
- Similar companies6
Updated 7 Oct 2026 · 7 sources